Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | BRD-K48334597 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.7 |
mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | BI-2536 | FIMM | pan-cancer | AAC | 0.046 | 0.7 |
mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | AZD8055 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.7 |
mRNA | triptolide | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.7 |
mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.01 | 0.7 |
mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |